ID   COG-AR-359
AC   CVCL_RS25
SY   COGAR359
DR   cancercelllines; CVCL_RS25
DR   Cell_Model_Passport; SIDM01488
DR   DepMap; ACH-001289
DR   Wikidata; Q54813966
RX   CelloPub=CLPUB00418;
WW   https://www.cccells.org/tables/Brain.php
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 53 hours (CelloPub=CLPUB00418).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): COG; DepMap
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11,14
ST   D18S51: 15,16
ST   D19S433: 14,15
ST   D21S11: 31.2
ST   D2S1338: 20,25
ST   D3S1358: 14,15
ST   D5S818: 9,10
ST   D7S820: 9,10
ST   D8S1179: 13,15
ST   FGA: 20,21
ST   Penta D: 12,15
ST   Penta E: 13,14
ST   TH01: 8,9.3
ST   TPOX: 8,10
ST   vWA: 17,19
DI   NCIt; C6906; Atypical teratoid/rhabdoid tumor
DI   ORDO; Orphanet_99966; Atypical teratoid rhabdoid tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RS26 ! COG-AR-382
SX   Male
AG   Children
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   CelloPub=CLPUB00418;
RA   Xu J.-Y., Erdreich-Epstein A., Biegel J.A., Reynolds C.P.;
RT   "Fenretinide combined with thiotepa is active against 3 newly
RT   established atypical teratoid rhabdoid tumor cell lines that manifest
RT   high-level multidrug resistance.";
RL   Cancer Res. 68 Suppl. 9:3743-3743(2008).
//